Am J Trop Med Hyg by ACT Consortium Drug Quality Project Team and the IMPACT2 Study Team
Am. J. Trop. Med. Hyg., 92(Suppl 6), 2015, pp. 75–86
doi:10.4269/ajtmh.14-0544
Copyright © 2015 by The American Society of Tropical Medicine and Hygiene
Quality of Artemisinin-Containing Antimalarials in Tanzania’s Private Sector—Results
from a Nationally Representative Outlet Survey
ACT Consortium Drug Quality Project Team and the IMPACT2 Study Team
Departments of Clinical Research, Disease Control, Global Health and Development and Infectious Disease Epidemiology,
London School of Hygiene & Tropical Medicine, London, United Kingdom; Division of Parasitic Diseases and Malaria,
U.S. Centers for Disease Control and Prevention, Atlanta, Georgia; School of Chemistry and Biochemistry,
Georgia Institute of Technology, Atlanta, Georgia; Ifakara Health Institute, Dar es Salaam, Tanzania
Abstract. Ensuring that artemisinin-containing antimalarials (ACAs) are of good quality is a key component of
effective malaria treatment. There are concerns that a high proportion of ACAs are falsified or substandard, though
estimates are rarely based on representative data. During a nationally representative survey in Tanzania, ACAs were
purchased from private retail drug outlets, and the active pharmaceutical ingredient (API) was measured. All 1,737
ACAs contained the labeled artemisinin derivative, with 4.1% being outside the 85–115% artemisinin API range defined
as acceptable quality. World Health Organization (WHO) prequalified drugs had 0.1 times the odds of being poor quality
compared with non-prequalified ACAs for the artemisinin component. When partner components of combination
therapies were also considered, 12.1% were outside the acceptable API range, and WHO prequalified ACAs had 0.04
times the odds of being poor quality. Although the prevalence of poor quality ACAs was lower than reported elsewhere,
the minority of samples found to be substandard is a cause for concern. Improvements in quality could be achieved by
increasing the predominance of WHO prequalified products in the market. Continued monitoring of quality standards
is essential.
INTRODUCTION
Artemisinin-containing antimalarials† (ACAs) are acknowl-
edged to be highly efficacious for malaria treatment.
Artemisinin-based combination therapies (ACTs) are the rec-
ommended first-line treatments for uncomplicated Plasmodium
falciparum malaria1 because artemisinin derivatives alone
require at least 7 days of treatment compared with 3 for ACT,
and because monotherapy use is thought to contribute to the
development of artemisinin resistance. Parenteral artesunate
monotherapy is recommended for initial treatment of severe
cases followed by a complete course of oral ACT.2
Ensuring that ACAs are of good quality is therefore a key
component in delivering effective malaria case management,
but there are concerns that a high proportion may be of poor
quality. Although there is debate about precise terminology,
poor quality drugs can be considered to fall into two broad
categories. Falsified drugs carry false representations of their
source or identity, and often contain none of the stated active
ingredient.3 Substandard drugs are genuine medicines that do
not meet the specifications outlined by an accepted pharma-
copeia, and contain sub- or supra-therapeutic doses of the
active pharmaceutical ingredient (API).4 This may be due to
several reasons including poor manufacturing practices and
degradation during transport and storage.
Since 2010, falsified and substandard antimalarials have
been reported with increasing frequency, especially in the
private for-profit sector of malaria-endemic countries.5–9
However, robust estimates of ACA quality are not available,
given the limited data and the tendency to generalize broadly
from small-scale, non-representative studies. Analysis of a
database of antimalarial quality reports found that 30% were
of poor quality, though results varied widely, and less than 5%
of the studies used random sampling techniques.10 Reports of
falsified and substandard antimalarials in the private sector
cause alarm as these providers are a common source for treat-
ment of fever, and supply a large proportion of antimalar-
ials.11,12 For example, in a study of treatment-seeking behavior
for children with fever in six African countries, between 17%
and 53% caregivers reported attending the private for-profit
sector.13 Drug quality may be particularly problematic in the
private sector, as private retailers are under less scrutiny
than the public sector and procurements are usually not
state-supported.14
Concerns about drug quality are not limited to antimalar-
ials; it has been estimated that up to 15% medicines distrib-
uted globally are falsified.15 However, poor quality ACAs
represent a particularly important public health issue in
malaria-endemic countries, as they can result in ineffective
treatment of malaria, leading to increased mortality and mor-
bidity, as well as potentially contributing to antimalarial drug
resistance because of suboptimal dosing. Antimalarial drug
resistance was first documented in southeast Asia in the early
1960s,16,17 and subsequently in sub-Saharan Africa in the
early 1980s.18,19 Of great concern is the recent documentation
of resistance to artemisinin in southeast Asia,20–24 which could
heavily compromise malaria control efforts if it were to spread
beyond the Greater Mekong subregion. Therefore, assuring
continued quality of ACAs dispensed to malaria patients is of
the utmost importance.
As noted above, the majority of studies of antimalarial drug
quality in the private sector have used convenience or purpo-
sive sampling,25–27 and as a result should not be generalized to
the overall population of drug outlets. Where random sam-
pling has been used, in many cases the sampling frame is not
clearly specified or the sample size is insufficient to provide
robust estimates of prevalence or associations with risk fac-
tors.7,25–30 These previous studies offer valuable preliminary
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data, and have in some cases served an important purpose in
alerting drug regulatory authorities to cases of falsified and
substandard products. However, they may substantially over-
or underrepresent the true prevalence of poor drug quality
on a national level, leading to inappropriate or inadequate
policy response. The costs of conducting a nationally repre-
sentative survey of outlets can be high, but in recent years
there has been an increase in the number of such surveys with
the primary objective of measuring antimalarial availability,
price, and market share.12,31 We used one such survey in
mainland Tanzania in 2010 as a basis for the collection of a
representative sample of ACAs to estimate the prevalence of
poor quality products in private retail outlets and the associ-
ated risk factors.
In Tanzania, an estimated 54% people who sought treat-
ment of fever visited a retail drug outlet in 2012.32 At this
time, Tanzania had three types of retail drug outlets: Part
One Pharmacies (hence forward referred to as pharmacies),
which should be run by a pharmacist and can stock most
medicines; duka la dawa baridi (DLDB), meaning “medicine
shop”, which can officially only stock over-the-counter medi-
cines; and accredited drug dispensing outlets (ADDOs),
which are DLDBs that have undergone training and been
upgraded, and are allowed to sell over-the-counter products
and a select number of prescription-only medications.33
ACAs are prescription-only medicines in Tanzania and, in
general, only permitted in pharmacies with the exception of
the first-line antimalarial, artemether–lumefantrine (Alu),
which is allowed in ADDOs. In practice, prescriptions are
rarely presented when purchasing prescription-only medi-
cines.34 Although not officially permitted, many DLDB also
stocked Alu, as the National Malaria Control Programme
recognized that these outlets provided an important source
of antimalarials for many people.35 Oral artemisinin-based
monotherapies have been banned, but injectable preparations
for treatment of severe malaria are still permitted in pharma-
cies. General retailers are not officially allowed to stock anti-
malarials, but occasionally do so.35
Several studies have highlighted the presence of poor qual-
ity antimalarials in Tanzania,36–38 including one report of a
falsified ACA.39 The only previous nationally representative
study in 2005 showed that 13.4% sulfadoxine–pyrimethamine
(SP) samples were substandard, together with 23.8% quinine
samples and 7.5% amodiaquine samples, though no falsified
medicines were detected, and all ACAs tested contained the
stated amount of active ingredient.40 Since 2005, stocking of
ACAs in the Tanzanian private sector has substantially
increased,35 highlighting the importance of rigorous and
repeated assessment of ACA quality.12
METHODS
Outlet survey. A nationally representative outlet survey
was conducted in 2010 as part of the Independent Evaluation
of the Affordable Medicines Facility–malaria (AMFm), a
multi-country antimalarial subsidy program.12 The outlet sur-
vey covered public, private not-for-profit, and private for-
profit antimalarial outlets, but we focus here on the private
for-profit sector (pharmacies, DLDB, ADDO, and general
retailers) where ACA samples were collected. Data collection
took place between September and November 2010 before
AMFmwas implemented. In total, 48 wards throughout main-
land Tanzania’s 21 regions‡ were randomly selected with
probability proportional to population size, stratified by
urban/rural location, and every outlet with the potential to
sell antimalarials was visited in selected wards. Outlets were
identified using official lists, by consulting with district phar-
macists and other local leaders and by driving or walking
down every street within a ward to locate all outlets. Wards
were designated as urban or rural based on National Bureau
of Statistics Census classifications. Every pharmacy in the
district in which the ward was located was also visited, as
pharmacies were relatively few in number but thought to be
a major source of antimalarials.
The sample size was determined based on the needs of the
independent evaluation (full details available in Tougher and
others12), which required 305 outlets stocking antimalarials
in both urban and rural domains. Estimates of the average
numbers of outlets per ward were used to estimate the
number of wards required to reach this target, leading to the
selection of 9 urban and 39 rural wards.
After verbal informed consent, full interviews were con-
ducted in outlets with an antimalarial in stock at the time of
visit or within the previous 3 months, with data collected using
personal digital assistants (PDAs). Questions about outlet
characteristics were asked using a structured questionnaire,
and details about every antimalarial in stock at the time of
visit were recorded.
Collection of ACA samples. A sample of every ACA pres-
ent at the time of visit was purchased from every private
for-profit outlet that reported stocking any ACAs. For pre-
packaged ACAs, one packet for each age group was pur-
chased; for ampoules/vials, suppositories, and packets of oral
pediatric granules for suspension, at least six units were pur-
chased; and for bottles of syrups and powders for suspensions
one bottle was purchased.
Each drug sample was sealed in a waterproof bag with
desiccant at the time of purchase. All samples were boxed
and stored at ambient temperature for maximum 3 months
before being sent to the London School of Hygiene & Tropi-
cal Medicine (LSHTM; United Kingdom) by air. At LSHTM,
samples were stored in the dark at ambient temperatures
(22°C) until and during analysis.
Laboratory analysis.Wemeasured the quantity of API pres-
ent for all artemisinin derivatives. In addition, we measured the
API amount for partner drugs in selected ACTs. Because of
capacity constraints, it was necessary to limit the partner
analysis to the most common partner drugs for each generic
artemisinin ingredient: lumefantrine, piperaquine, and mef-
loquine (used in the ACTs Alu, artemisinin–piperaquine,
dihydroartemisinin–piperaquine, artesunate–amodiaquine and
artesunate–mefloquine).
The physical dimensions and weight of each antimalarial tab-
let were recorded prior to processing for analysis, to fully docu-
ment sample characteristics before preparation. Formulations
were analyzed for the amount of each API present using high-
performance liquid chromatography with ultraviolet photo-
diode array detection (HPLC-UV-PDA). Each tablet was
pulverized, and dissolved in solvent depending on the stated
‡Tanzania had 21 regions at the time of the study, though this has
subsequently been increased to 25. Results are presented based on
the 21 regions at the time of data collection.
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API: artesunate, artemether, dihydroartemisinin, amodiaquine,
sulfamethoxypyrazine/pyrimethamine, and SP were dissolved
in methanol; samples containing lumefantrine (LUM) were
dissolved in 10% acetic acid in methanol, mefloquine (MF) in
methanol/2.0 N hydrochloric acid (MeOH/2.0 N HCl; v/v)
and piperaquine (PIP) in methanol/0.1 M HCl (1:1; v/v). Sol-
vent extracts were sonicated followed by centrifuging, and the
supernatant injected into the HPLC column to determine the
amount of API present. Syrups, powders, suspensions and
suppositories were dissolved in methanol. Injectables where
the stated API carrier was coconut oil were also dissolved in
methanol, with injectables where the carrier was peanut oil
dissolved in isopropanol: hexane (v/v; 16:1).
All samples analyzed at LSHTM were sent to the U.S.
Centers for Disease Control and Prevention Laboratories,
Atlanta, GA, and the Georgia Institute of Technology,
Atlanta, GA, for HPLC confirmatory analysis and mass spec-
trometry (MS) screening, respectively (both groups were
blinded to the LSHTM results). Additional laboratory analy-
sis details are given in Supplemental Information.
Data analysis. Data analysis was conducted in Stata ver-
sion 12 (StataCorp LP, College Station, TX). The primary
outcome was “drug quality,” defined as the percentage of the
stated amount of API detected in each drug component. Under
the World Health Organization (WHO) International Pharma-
copoeia, the acceptable range for artemisinin-based antimalar-
ials and their companion drugs is to contain 90.0–110.0% active
ingredient stated on the label. Reflecting the typically observed
experimental variation in HPLC laboratory testing where less
than 10 samples of each ACA formulation were tested, we
adopted a wider tolerance band of 85–115% for the purposes
of this study. Thus, samples were considered to be of “accept-
able quality” in terms of the artemisinin derivative component
if these samples contained 85–115% artemisinin derivative
API as labeled, and acceptable quality in terms of both the
artemisinin derivative and partner drug components if they
contained 85–115% API, as labeled for both components.
Results were weighted to reflect the sampling strategy for
the outlet survey.35 The analysis was corrected for clustering
at the district level and urban/rural stratification using Stata
SVY commands. Statistical tests were evaluated at P £ 0.05
level of precision.
The outlet survey included data on several potential risk
factors for poor quality medicines, including characteristics of
the products and the outlets from which they were purchased.
Outlet characteristics included type of outlet (pharmacy, drug
store [DLDB or ADDO], general store), and urban or rural
location. Product characteristics included generic components,
date of manufacture, date of expiry, stated manufacturer,
stated country of manufacture, dose form (e.g., suspension,
tablet, injectable), whether the drug was WHO prequalified at
the time of the survey, whether the drug was a fixed-dose
combination, and retail price. “Cheap” drugs were defined as
drugs with a price in the lowest quartile of all ACAs sampled,
stratified by dosage form. Prices were calculated using adult
equivalent treatment doses (AETDs), the amount of a drug
needed to completely treat a 60-kg adult.31 For example, to
calculate the price per AETD of a pediatric package of Alu
with six standard tablets (20 mg artemether and 120 mg
lumefantrine), the price would be multiplied by four to calcu-
late the cost for an adult equivalent dose of 24 tablets.
The association between poor ACA quality and outlet and
product characteristics was examined using regression analysis,
taking survey design into account. Unordered categorical vari-
ables were tested using the Wald test to estimate the overall
statistical significance of categorical variables, for example,
dose form. Sensitivity analysis was undertaken using a narrower
API range for acceptable quality of 90–110% stated API.
Ethical approval. Ethical approval was obtained from the
Tanzanian National Institute for Medical Research, the Insti-
tutional Review Board of the Ifakara Health Institute, the
London School of Hygiene & Tropical Medicine Research
Ethics Committee, and from the Institutional Review Board
of ICF International.
RESULTS
Description of sample. In total, 3,029 private for-profit
retail outlets were visited, of which 512 had an antimalarial in
stock on the day of visit (Table 1). From the outlets stocking
ACAs, 1,737 ACAs were purchased and analyzed for API
content: 55 ACAs were documented in outlets but not ana-
lyzed because either it was not possible to purchase the ACA
or the purchased ACA could not be linked to the relevant
Table 1
Description of outlets visited and antimalarials obtained
Type of outlets
Outlets
enumerated
Outlets meeting screening
criteria and interviewed*
Outlets with antimalarials in
stock on day of visit
Outlets with artemisinin-containing
antimalarials in stock on day of visit
Artemisinin-containing
antimalarials audited
Total number of ACAs
purchased and analyzed
Pharmacies
Urban 261 215 214 206 1,601 1,554
Rural 13 8 8 8 54 53
Total 274 223 222 214 1,654 1,607
Drug stores (DLDBs/ADDOs)
Urban 99 85 85 24 77 73
Rural 172 147 144 30 55 52
Total 271 232 229 54 132 125
General retailers
Urban 759 1 1 0 0 0
Rural 1,725 80 60 4 6 5
Total 2,484 81 61 4 6 5
Urban total 1,119 301 300 230 1,678 1,627
Rural total 1,910 235 212 42 114 110
Total 3,029 536 512 272 1,792 1,737
ACAs = artemisinin-containing antimalarials; ADDOs = accredited drug dispensing outlets; DLDBs = duka la dawa baridi.
*Outlets were deemed to meet screening criteria if they had an antimalarial in stock or had stocked an antimalarial in the previous 3 months.
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outlet at the time of analysis. By generic class, the most
frequently analyzed ACA was artemether: 604 doses were
analyzed, of which 504 were stated to be Alu, the first-line
antimalarial (Table 2). In all, samples from 177 different stated
batches were analyzed.
Outlet and product characteristics. Of all outlets with any
antimalarials in stock at the time of the visit, nearly all phar-
macies reported having at least one member of staff with a
health-related qualification (97.6%), compared with only 7.0%
general retailers (Table 3). Of all outlets with antimalarials in
stock, 21.6% had an ACA, and ACA-stocking outlets were
identified in 16 of the 21 regions. Stocking patterns varied
substantially across outlet types, with 96.0% pharmacies stock-
ing an ACA, compared with 24.5% drug stores (DLDB or
ADDO) and 4.6% general retailers. A WHO prequalified
ACT was stocked by 71.0% pharmacies, 11.9% drug stores,
and 4.6% general retailers. No drug stores or general retailers
stocked artemisinin monotherapies, but 39.8% pharmacies
stocked injectable artemisinin monotherapies and 2.1% phar-
macies stocked oral artemisinin monotherapy.
Overall, 58.1% ACAs were stocked by drug stores, and
67.7% were from urban areas (Table 4). The majority of
products were combination therapies (97.0%), and were in
tablet form (86.1%). The most commonly stated regions of
manufacture were Asia (45.3%), Africa (27.6%), and Europe
(20.7%). Only a quarter of ACAs were WHO prequalified
(25.7%). The largest proportions of non-prequalified ACAs
were stated to be manufactured in Asia (43.9%) and Africa
(36.7%), while a smaller proportion were stated to be manu-
factured in Europe (18.9%).
Only 2.0% ACAs had expired at the time of purchase.
However, 67.4% had expired by the time of analysis because
of delays in processing and analyzing the samples. Of these,
the majority had expired within 12 months of analysis (43.5%),
but a substantial minority had expired more than 1 year before
the time of analysis (23.5%). The implications of these delays
are discussed below.
Drug quality based on artemisinin component only. All
drugs analyzed contained the stated artemisinin derivative.
Overall 95.9% samples contained between 85% and 115% rec-
ommended API for the artemisinin component, with 1.6% con-
taining below 85% and 2.4% containing above 115% (Figure 1).
By type of artemisinin derivative, 97.9% artemether and 93.9%
artesunate-based drugs were of acceptable quality by this defi-
nition. Dihydroartemisinin-based drugs had the highest per-
centage of products with below 85% stated artemisinin API,
while artesunate-containing drugs had the highest percentage
of products with more than 115% stated artemisinin API.
The MS analysis conducted at the Georgia Institute of
Technology confirmed that all samples contained the stated
artemisinin and partner active ingredient, and no other active
ingredients were identified. There was a reasonable level of
agreement between the HPLC analyses conducted at LSHTM
and the U.S. Centers for Disease Control and Prevention
(Supplemental Information).
Figure 2A shows the proportion of poor quality ACAs by
region in Tanzania based on the artemisinin component. Poor
Table 2
Description of artemisinin-containing antimalarial samples analyzed
Active ingredient Pharmacy
Drug store
(DLDB/ADDO)
General
retailer Total
Artemether
Artemether monotherapy 100 0 0 100
Alu 463 36 5 504
Total 563 36 5 604
Artemisinin
Artemisinin monotherapy 0 0 0 0
Artemisinin–napthoquine 121 4 0 125
Artemisinin–piperaquine 160 13 0 173
Total 281 17 0 298
Artesunate
Artesunate monotherapy 11 0 0 11
Artesunate–amodiaquine 32 5 0 37
Artesunate–mefloquine 295 15 0 310
Artesunate–SP 159 24 0 183
Total 497 44 0 541
Dihydroartemisinin
Dihydroartemisinin–
piperaquine
266 28 0 294
Total 266 28 0 294
Total 1,607 125 5 1,737
ADDOs = accredited drug dispensing outlets; Alu = artemether–lumefantrine; DLDBs =
duka la dawa baridi; SP = sulfadoxine–pyrimethamine.
Table 3
Characteristics of outlets with antimalarials in stock on the day of visit
Type of outlets
Median number
of staff [IQR]
At least one member
of staff with health-related
qualification* (95% CI)
At least one ACA
in stock (95% CI)
At least one ACT in
stock (95% CI)
At least one WHO prequalified
ACA in stock (95% CI)
At least one artemisinin monotherapy
in stock (95% CI)
Pharmacies
Urban 4 [3, 6] 97.5 (91.3–99.3) 95.8 (90.9–98.1) 95.8 (90.9–98.1) 71.1 (62.3–78.5) 40.2 (29.3–52.2)
Rural 4 [4, 4] 100 100 100 70.1 (32.7–91.9) 50.3 (14.6–85.6)
Total 4 [3, 6] 97.6 (92.3–99.3) 96.0 (91.3–98.2) 96.0 (91.3–98.2) 71.0 (62.5–78.2) 40.6 (30.0–52.2)
Drug stores (DLDBs/ADDOs)
Urban 2 [1, 2] 96.6 (88.5–99.0) 26.2 (16.4–39.2) 26.2 (16.4–39.2) 13.8 (8.2–22.2) 0
Rural 1 [1, 2] 84.9 (77.5–90.1) 23.8 (12.5–40.7) 23.8 (12.5–40.7) 11.1 (7.5–16.1) 0
Total 2 [1, 2] 88.4 (82.9–92.3) 24.5 (15.7–36.3) 24.5 (15.7–36.3) 11.9 (8.7–16.1) 0
General retailers
Urban 2 [2, 2] 0 0 0 0 0
Rural 1 [1, 2] 7.1 (2.7–17.0) 4.6 (2.1–9.8) 4.6 (2.1–9.8) 4.6 (2.1–9.8) 0
Total 1 [1, 2] 7.0 (2.7–16.8) 4.6 (2.1–9.8) 4.6 (2.1–9.8) 4.6 (2.1–9.8) 0
Urban total 2 [1, 2] 96.0 (89.8–98.5) 35.6 (25.4–47.5) 35.6 (25.4–47.5) 21.6 (15.8–28.7) 5.6 (3.2–9.7)
Rural total 1 [1, 2] 57.2 (43.2–70.1) 17.1 (9.0–30.1) 17.1 (9.0–30.1) 8.9 (6.2–12.6) 0.1 (0.0–0.4)
Total 1 [1, 2] 66.6 (55.1–76.5) 21.6 (15.0–30.0) 21.6 (15.0–30.0) 12.0 (9.3–15.3) 1.5 (0.8–2.7)
ACA = artemisinin-containing antimalarial; ACT = artemisinin-based combination therapy; ADDOs = accredited drug dispensing outlets; CI = confidence interval; DLDBs = duka la dawa
baridi; WHO =World Health Organization.
*A health-related qualification is defined as pharmacy-, nurse-, or medical-doctor-related training. Pharmacy-related training includes studying to a certificate or diploma level. Nurse-
related training includes studying nursing to a certificate level (nurse aid) and diploma level. Medical doctor training includes clinical officers who studied medicine to a diploma level and fully
qualified physicians.
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quality ACAs were purchased from 10 of the 16 regions where
ACAs were found. In regions where poor quality ACAs
were found, the prevalence ranged from below 1% to 9%.
Table 5 shows the percentage of poor quality drugs based
on the artemisinin component by risk factor. On the basis of
this bivariate analysis, four risk factors were associated with
poor quality at P < 0.05: not being WHO prequalified, being
relatively expensive (not in lowest price quartile), dose form,
and type of artemisinin derivative. Only 0.5% WHO pre-
qualified drugs were of poor quality, compared with 5.4% of
those not prequalified. Nearly one-third (29.6%) of pediatric
granules were of poor quality, compared with 3.4%, 5.4%, and
Table 4
Characteristics of artemisinin-containing antimalarial samples analyzed, by generic content
Artemether
(N = 604)
Artemisinin
(N = 248)
Artesunate
(N = 541)
Dihydroartemisinin
(N = 294)
All artemisinin-containing
antimalarials (N = 1,737)
Selected ACTs for which
partner drug was also
analyzed (N = 1,281)
Outlet type
Pharmacies 42.8 (25.9–61.6) 53.8 (33.0–73.3) 33.4 (16.6–56.0) 34.1 (19.8–51.9) 39.1 (23.6–57.1) 40.9 (25.7–57.9)
Drug stores 48.5 (30.7–66.8) 46.3 (26.7–67.0) 66.6 (44.1–83.4) 65.9 (48.1–80.2) 58.1 (39.9–74.4) 55.2 (37.9–71.3)
General retailers 8.7 (2.4–27.4) 0 0 0 2.8 (0.7–10.5) 4.0 (1.0–14.5)
Location
Urban 63.2 (43.3–79.4) 86.8 (53.4–97.4) 65.3(28.2–90.0) 66.8 (32.8–89.3) 67.7 (41.8–85.9) 71.8 (52.4–85.4)
Rural 36.8 (20.6–56.7) 13.2 (2.6–46.6) 34.7 (10.0–71.8) 33.2 (10.8–67.2) 32.3 (14.1–58.2) 28.3 (14.6–47.6)
Monotherapy/ACT
Monotherapy 8.5 (4.6–15.2) 0 0.9 (0.5–1.7) 0 3.0 (1.7–5.2) 0
ACT 91.5 (84.8–95.4) 100 99.1 (98.4–99.5) 100 97.0 (94.9–98.3) 100
Generic name
Artemether − − − − 31.7 (23.0–41.9) 41.6 (33.6–50.1)
Artemisinin − − − − 12.9 (9.2–17.7) 12.5 (9.3–16.4)
Artesunate − − − − 37.4 (27.9–48.0) 20.0 (15.0–26.0)
Dihydroartemisinin − − − − 18.1 (14.2–22.7) 26.0 (17.9–36.1)
Dosage form
Tablet 63.9 (52.1–74.2) 100 93.4 (87.2–96.8) 100 86.1 (80.6–90.3) 84.3 (77.6–89.3)
Suspension 27.6 (18.8–38.5) 0 0 0 8.7 (6.1–12.4) 12.6 (9.5–16.5)
Injectable 8.5 (4.6–15.2) 0 0.7 (0.4–1.4) 0 3.0 (1.7–5.2) 0
Granule 0 0 5.9 (2.6–12.8) 0 2.2 (1.0–5.0) 3.2 (1.4–7.1)
WHO prequalified 61.4 (49.5–72.2) 0 16.8 (7.9–32.2) 0 25.7 (18.7–34.4) 27.7 (19.4–38.0)
Region of stated country
of manufacture
Asia 21.2 (12.5–33.6) 99.8 (99.2–99.9) 15.9 (7.1–31.7) 100 45.3 (41.1–49.5) 49.0 (40.1–58.0)
Africa 31.9 (22.4–43.2) 0.0 (0.0–0.6) 46.8 (27.4–67.1) 0 27.6 (20.4–36.2) 12.4 (9.3–16.4)
Europe 26.6 (20.0–34.5) 0.1 (0.0–0.8) 37.3 (21.7–56.0) 0 20.7 (15.0–27.8) 29.5 (23.3–36.6)
United States 19.3 (7.7–40.6) 0 0.0 (0.0–0.7) 0 6.1 (2.2–16.2) 8.8 (3.2–22.1)
Unknown 1.1 (0.5–2.1) 0 0.0 (0.0–0.4) 0 0.4 (0.2–0.7) 0.3 (0.1–0.7)
Expired at time of purchase 5.3 (2.0–13.3) 0.2 (0.0–1.0) 0.4 (0.0–1.8) 1.2 (0.5–2.7) 2.0 (0.8–5.1) 2.8 (1.1–6.8)
Expired at time of analysis 76.5 (66.2–74.3) 29.3 (18.3–43.4) 57.4 (35.6–76.6) 100 67.4 (56.5–76.8) 83.3 (75.8–88.8)
Price per AETD
< 25th percentile 39.4 (25.0–56.0) 0.3 (0.0–1.0) 30.2 (7.6–69.4) 2.1 (0.3–14.4) 24.2 (12.6–41.4) 18.2 (10.3–30.0)
ACTs = artemisinin-based combination therapies; AETD = adult equivalent treatment dose; DHA = dihydroartemisinin; WHO =World Health Organization.
Figure 1. Content of active pharmaceutical ingredient as a percentage of stated content for artemisinin components of all artemisinin-
containing antimalarials analyzed.
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Figure 2. Proportion of (A) poor quality artemisinin-containing antimalarials (ACAs) by region based on artemisinin component only, and
(B) poor quality artemisinin-based combination therapies (ACTs) by region based on artemisinin component and partner drug for selected ACTs
(poor quality defined as less than 85% or greater than 115% of stated API).
Table 5
Percentage of artemisinin-containing antimalarial samples that were poor quality by risk factor, and ORs of being poor quality based on
artemisinin component only
N Number of poor quality Percentage poor quality Unadjusted OR P value
Outlet type 0.3
Pharmacies 1,601 85 5.7 (4.6–7.1) 1
Drug stores 124 4 3.2 (1.3–7.9) 0.6 (0.2–1.6)
General retailers 5 0 0 −
Location 0.2
Urban 1,621 85 5.0 (3.4–7.4) 1
Rural 109 4 2.3 (0.8–6.8) 0.5 (0.1–1.5)
Monotherapy/ACT 0.5
Monotherapy 1,620 86 2.9 (1.2–6.7) 1
ACT 110 3 4.1 (2.7–6.3) 1.4 (0.5–4.1)
Generic type 0.02
Artemether 599 16 2.1 (0.9–4.8) 1
Artemisinin 298 4 2.5 (0.5–12.7) 1.2 (0.2–9.3)
Artesunate 539 46 6.1 (2.7–13.1) 3.1 (0.7–12.4)
Dihydroartemisinin 294 23 4.7 (2.6–8.4) 2.3 (1.4–4.0)
WHO prequalified 0.002
No 1,442 85 5.4 (3.4–8.5) 1
Yes 308 4 0.5 (0.1–1.9) 0.1 (0.02–0.4)
Dose form 0.02
Tablet 1,385 55 3.4 (1.8–6.3) 1
Suspension 192 11 5.4 (1.7–15.8) 1.6 (0.4–7.3)
Injectable 107 3 3.0 (1.3–6.9) 0.9 (0.3–2.8)
Granule 46 20 29.6 (9.9–61.5) 10.6 (1.7–65.9)
Stated region of manufacture 0.1
Asia 850 32 3.0 (1.8–5.1) 1
Africa 435 15 2.3 (0.9–5.4) 0.8 (0.4–1.6)
Europe 412 41 10.2 (4.3–22.1) 3.6 (1.0–13.3)
United States 17 1 0.01 (0.0–5.0) 0.2 (0.02–1.7)
Expired at date of purchase –
Not expired 1,703 89 4.2 (2.8–6.3) 1
Expired 26 0 0 Omitted
Expired at date of analysis 0.05
Not expired 644 10 1.8 (0.7–4.8) 1
Expired 1,083 79 5.2 (3.5–7.8) 3.0 (1–8.7)
Price per AETD 0.03
< 25th percentile 133 9 1.5 (0.6–3.9) 1
³ 25th percentile 1,599 80 4.9 (3.3–7.2) 3.3 (1.1–9.8)
ACT = artemisinin-based combination therapy; AETD = adult equivalent treatment dose; WHO =World Health Organization.
Poor quality defined as less than 85% or greater than 115% of stated API.
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3.0% for tablets, suspensions, and injectables, respectively.
There was less variation in poor quality by type of artemisinin
derivatives: 6.1% artesunate derivatives were of poor quality
compared with 4.7%, 2.5%, and 2.1% for dihydroartemisinin,
artemisinin, and artemether, respectively. Type of outlet,
urban/rural location, whether the product was an ACT rather
than a monotherapy, and stated region of manufacture were
not found to be associated with poor quality. Expiry at date of
analysis was of borderline significance.
Data were too sparse for robust multivariable analysis.
However, given the possible association of expiry by date of
analysis with quality, we investigated the relationship between
drug quality and other risk factors by recalculating their odds
ratios (ORs) adjusting for expiry by date of analysis. This
adjusted analysis was performed for all other risk factors where
P < 0.2 in the bivariate analysis (Supplemental Table 1).
Adjustment led to no major change in ORs, with the exception
of dihydroartemisinin where the OR decreased from 2.3 to 1.9.
Table 6
Percentage of selected ACTs by quantity of stated API for artemisinin component and partner drug
(a) All ACTs analyzed (N = 1,281)
Partner drug
Artemisinin component %API 55–65 65–75 75–85 85–115 115–125 > 125 Total
55–65 < 0.1 0 0.1 < 0.1 < 0.1 0 0.2
65–75 0 0.1 0 < 0.1 0 0 0.2
75–85 0 0 < 0.1 1.7 0.1 0 1.9
85–115 0 0 3.3 87.9 2.7 0.6 94.4
115–125 0 < 0.1 0 1.4 1.5 0 2.9
> 125 0 0 0 0.2 0.1 0 0.3
Total < 0.1 0.2 3.4 91.3 4.5 0.6 100
(b) Alu (N = 504)
Lumefantrine
Artemether drugs %API 55–65 65–75 75–85 85–115 115–125 > 125 Total
55–65 0 0 0 0 0 0 0.0
65–75 0 0 0 0 0 0 0.0
75–85 0 0 0 < 0.1 0 0 < 0.1
85–115 0 0 0.2 96.9 1.0 0 98.0
115–125 0 0 0 1.4 0 0 1.4
> 125 0 0 0 0.6 0 0 0.6
Total 0.0 0.0 0.2 98.9 1.0 0.0 100
(c) Artemisinin–piperaquine (N = 173)
Piperaquine
Artemisinin %API 55–65 65–75 75–85 85–115 115–125 > 125 Total
55–65 0 0 0 0 0 0 0.0
65–75 0 0 0 0 0 0 0.0
75–85 0 0 0 3.6 0 0 3.6
85–115 0 0 0.9 88.5 2.7 4.3 96.4
115–125 0 0 0 0 0 0 0.0
> 125 0 0 0 0 0 0 0.0
Total 0.0 0.0 0.9 92.1 2.7 4.3 100
(d) Artesunate–mefloquine (N = 310)
Mefloquine
Artesunate %API 55–65 65–75 75–85 85–115 115–125 > 125 Total
55–65 <0.1 0 0.6 <0.1 0.2 0 1.0
65–75 0 0.6 0 0.4 0 0 1.0
75–85 0 0 0 0.9 0.6 0 1.5
85–115 0 0 0.3 80.8 3.7 < 0.1 84.9
115–125 0 0.2 0 3.4 7.5 0 11.2
> 125 0 0 0 0 0.6 0 0.6
Total < 0.1 0.8 0.9 85.5 12.6 < 0.1 100
(e) Dihydroartemisinin–piperaquine (N = 294)
Piperaquine
Dihydroartemisinin %API 55–65 65–75 75–85 85–115 115–125 > 125 Total
55–65 0 0 0 0 0 0 0.0
65–75 0 0 0 0 0 0 0.0
75–85 0 0 0.2 4.1 0 0 4.2
85–115 0 0 11.6 78.9 4.7 0.1 95.3
115–125 0 0 0 0.4 0 0 0.4
> 125 0 0 0 0 0 0 0.0
Total 0.0 0.0 11.8 83.4 4.7 0.1 100
ACT = artemisinin-based combination therapy; Alu = artemether–lumefantrine; API = active pharmaceutical ingredient.
The percentage of samples containing acceptable quantities of API for both the artemisinin component and partner drug is shown in bold.
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Only WHO prequalification remained significantly associated
with quality after this adjustment (OR 0.1, 95% confidence
interval [CI]: 0.01–0.34, P = 0.002).
Drug quality based on artemisinin and partner components.
Laboratory analysis was also conducted on three partner
drugs (lumefantrine, piperaquine, and mefloquine) used in
the ACTs Alu, artemisinin–piperaquine, dihydroartemisinin–
piperaquine, and artesunate–mefloquine. Considering both
artemisinin and partner drug quality, 87.9% ACTs were of
acceptable quality (Table 6) with 5.1% partner drugs contain-
ing higher than the 115% API limit and 3.7% below the 85%
API limit. A small proportion of drugs had components that
both fell either above (1.6%) or below (0.3%) the 85–115%
API range. Poor quality ACTs based on quality of either
component were purchased from 10 of the 16 regions where
ACTs were found, with prevalence ranging from 1.4% to
26.5%, across regions (Figure 2B).
Table 7 shows the proportion of ACTs that were of poor
quality based on both components by risk factor. As with the
analysis of artemisinin derivative components alone, not being
WHO prequalified, dose form, and type of artemisinin deriva-
tive were associated with poor quality based on both compo-
nents. In addition, expiry at date of analysis was also a risk
factor for poor quality when both components were consid-
ered. Around one-fifth of artesunate (19.2%)- and dihydroar-
temisinin (21.1%)-based ACTs were of poor quality. This was
nearly double the proportion of poor quality artemisinin-based
ACTs (11.6%), and almost seven times that for artemether-
based ACTs (3.1%). Price was of borderline significance.
Adjusting for expiry at date of analysis led to no major
changes in ORs, with the exception of Europe as stated coun-
try of manufacture where the OR decreased from 3.0 to 0.9
(Supplemental Table 2). The only risk factors remaining sig-
nificant at 0.05 level after adjustment were WHO prequalifi-
cation (OR 0.04, 95% CI: 0.01–0.2, P < 0.001) and type of
artemisinin derivative (OR ranged from 5.2 to 7.3, P = 0.01).
Sensitivity analyses. To determine how sensitive results
were to the percent API cutoffs used to define poor quality,
the analysis was repeated using a narrower range of 90–110%.
Using these tighter cutoffs, the percent of products defined as
poor quality on the basis of the artemisinin component would
have risen from 4.1% to 17.6% and on the basis of both
components in ACTs from 12.1% to 30.6% (Figure 3).
DISCUSSION
This study reports on the quality of artemisinin-containing
drugs collected in Tanzania in 2010 as part of a nationally
representative survey of private for-profit retail outlets. All
samples contained the stated artemisinin derivative, and the
majority contained between 85% and 115% stated amount
and were therefore considered of acceptable quality. No prod-
ucts contained an incorrect API. However, a substantial minor-
ity were substandard: 4.1% for the artemisinin component for
Table 7
Percentage of ACT samples that were poor quality by risk factor, and ORs of being poor quality based on both artemisinin and partner
components for selected ACTs
N Number of poor quality Percentage poor quality Unadjusted OR P value
Outlet type 0.4
Pharmacies 1,180 124 11.0 (9.6–12.6) 1
Drug stores 91 11 13.9 (7.4–24.5) 1.3 (0.6–2.6)
General retailers 5 0 0 −
Location 0.6
Urban 1,202 126 11.2 (8.3–15.0) 1
Rural 74 9 14.6 (4.7–36.8) 1.35 (0.38–4.84)
Generic type 0.04
Artemether 499 17 3.1 (1.3–7.5) 1
Artemisinin 173 14 11.6 (5.3–23.5) 4.0 (1.3–12.9)
Artesunate 310 65 19.2 (11.6–30.1) 7.3 (2.0–26.6)
Dihydroartemisinin 294 39 21.1 (11.1–36.4) 8.3 (2.6–25.9)
WHO prequalified < 0.001
No 1,015 130 16.4 (11.3–23.2) 1
Yes 261 5 0.8 (0.3–2.5) 0.04 (0.01–0.1)
Dose form 0.04
Tablet 1,040 99 11.8 (7.1–18.9) 1
Suspension 192 12 8.6 (2.9–22.6) 0.7 (0.2–2.6)
Injectable 0 0 − −
Granule 44 24 35.1 (10.1–72.1) 3.9 (0.7–21.9)
Stated region of manufacture 0.05
Asia 657 56 14.5 (7.9–25.2) 1
Africa 186 12 8.7 (2.9–22.9) 1.5 (0.6–4.0)
Europe 404 66 13.2 (7.2–23.1) 3.0 (0.9–10.1)
United States 17 1 0.6 (0.0–5.1) 0.1 (0.01–1.5)
Expired at date of purchase 0.2
Not expired 1,257 134 12.3 (8.1–18.2) 1
Expired 18 1 3.0 (0.3–22.4) 10.2 (0.02–2.1)
Expired at date of analysis 0.02
Not expired 303 15 5.7 (2.8–11.3) 1
Expired 972 120 13.5 (8.8–20.2) 2.57 (1.20–5.5)
Price per AETD 0.05
< 25th percentile 70 8 4.5 (1.3–15.0) 1
³ 25th percentile 1,206 127 13.7 (9.4–16.7) 3.36 (0.9–11.6)
ACT = artemisinin-based combination therapies; AETD = adult equivalent treatment dose. OR = odds ratio; WHO =World Health Organization.
Poor quality defined as less than 85% or greater than 115% of stated API.
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all ACAs and 12.1% if both the artemisinin derivative and the
partner components were considered for selected ACTs. Dis-
solution testing was not performed, so the bioavailability of the
samples was not measured. The results are not as alarming as
might have been expected from previous nonrepresentative
surveys. However, drug quality is likely to vary substantially
between countries and over time, so one should not assume
that these findings can be widely generalized. For example,
results from a contemporaneous representative study of
malaria-endemic areas in Cambodia also found that all ACAs
contained the stated artemisinin derivative, but a higher pro-
portion, 31.6%, were outside the API range of 85–115%.41
Studies in Nigeria have found products labeled as ACTs
containing no trace of the stated APIs in Enugu and Ilorin
states with falsified packaging (Harparkash Kaur, unpublished
results), with some products similar to the falsified CoartemÒ
first reported in Angola.42
A higher proportion of ACTs were considered poor quality
when the quality of the partner drugs was also measured. This
highlights the importance of testing both components of
ACTs. Moreover, we only had capacity to measure the levels
of lumefantrine, mefloquine, and piperaquine, so the quality
of other partners, such as SP, amodiaquine, and napthoquine,
remains unknown. Partner drug quality is a crucial concern, as
it is likely to affect the efficacy of ACTs, given that a 3-day
course of an artemisinin alone is insufficient to achieve a high
cure rate.43 In addition, low levels of the partner drug could
leave the artemisinin component unprotected, increasing the
likelihood for the development of artemisinin resistance. We
have not identified other studies reporting on the quality of part-
ner drugs within ACTs. However, there is substantial evidence of
poor quality in commonly used partner drugs such as SP and
mefloquine when manufactured as monotherapy products.39,44
The risk factors associated with a poor quality artemisinin
component were not being WHO prequalified, being rela-
tively expensive (not in lowest price quartile), dose form
(granules), and type of artemisinin derivative (artesunate). It
was notable that drug stores were not found to be more likely
than pharmacies to stock poor quality ACAs. There was also
no difference between the proportion of poor quality antima-
larials found in drug stores in regions where drug stores had
been upgraded to ADDOs and those which had yet to be
upgraded (data not shown). For partner drugs, risk factors
were similar to those for artemisinin components alone.
The high proportion of poor quality granular formulation
antimalarials were driven by non-prequalified poor quality
artesunate–mefloquine, which comprised about half of all
artesunate–mefloquine substandard samples.
The sheer volume of drugs sampled in this study and the
broad geographic distribution of the outlets from which they
were collected limited the speed at which they could be pro-
cessed for laboratory analysis. In addition, ACAs have a
stated short maximum shelf life of 24 months from the date
of production. However, despite the high proportion of prod-
ucts expired at analysis, a relatively small minority of these
were found to be substandard (5.3% for artemisinin compo-
nent, 13.5% for both components). Adjusting for expiry at
time of analysis did not have a major effect on the magnitude
of most ORs. However, after adjustment, only WHO prequal-
ification remained significantly associated with the quality of
the artemisinin component only, and only WHO prequalifica-
tion and type of artemisinin component were associated with
quality, when both components of ACTs were considered.
A further methodological limitation is that for each product
only one pack of tablets or six units of other formulations
were purchased for analysis in the laboratory, compared with
the 30 units recommended by USP.45 The rationale for this
more limited testing was the time constraints involved in
chemically analyzing this volume of samples. In addition, pur-
chasing large quantities of ACTs from relatively small medi-
cine stores could have affected access to antimalarials,
especially in remote areas. Reflecting this limitation, and rec-
ognizing that there is also added variability due to innate
variance in HPLC results, we used a relatively broad window
for the definition of “acceptable quality” of 85–115% to avoid
falsely identifying samples as poor quality. This is not to imply
that 85% stated API should be considered an adequate dose,
and means that we will have categorized some samples con-
taining inadequate API as “acceptable.” Had a narrower win-
dow of 90–110% been used, the percent of products defined
Figure 3. Content of active pharmaceutical ingredient as a percentage of stated content for artemisinin and partner components of all
artemisinin-containing antimalarials analyzed, with cutoffs described.
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as poor quality on the basis of the artemisinin component
would have risen from 4.1% to 17.6% and on the basis of both
components in ACTs from 12.1% to 30.6%. This high sensi-
tivity of the results to the API cutoffs highlights the need for
greater understanding about the therapeutic effects of API
variability, and the limitations of testing small numbers of
units for each sample.
Weak medicine regulatory systems have been observed in a
range of low- and middle-income countries,46–48 reflecting
lack of financial resources, manpower, and capacity.49 Capac-
ity to perform laboratory tests on all products entering the
market, let alone those available at retail level is therefore
inevitably constrained. However, these results indicate that
important improvements in quality can be achieved by ensur-
ing that only products meeting WHO prequalification are
registered and allowed onto the market. This could lead to
concerns that this would cause an increase in prices for con-
sumers. However, data from the Tanzanian survey showed
that the median price of WHO prequalified ACAs in tablet
form ($5.28 per AETD [interquartile range {IQR} $1.41–
$7.04]) was actually lower than the median price of non-
WHO prequalified tablet ACAs ($7.93 per AETD [IQR
$3.87–$12.67]).
The strength of this study was its large-scale and nationally
representative nature, reflecting the opportunity to add sam-
ple collection to an ongoing national survey. However, regu-
latory authorities may not routinely have access to such
survey teams. Moreover, the sheer volume of samples col-
lected would be unlikely to be feasible for analysis as part of
routine regulatory activities, and even in a research setting
leads to long processing times, which would poorly suit a
rapid policy response. By contrast, very small-scale conve-
nience samples, collected in response to a perceived threat,
frequently lead to alarmist reports overestimating the scale of
poor quality products. These reports could themselves have
negative consequences, such as undermining user confidence
in antimalarials altogether, or encouraging users to revert to
less effective drugs.
There is therefore a need to develop “smart” surveillance
techniques that provide both robust estimates of drug quality,
while being affordable and timely. For example, Newton and
others have suggested lot quality assurance sampling (LQAS)
of retail outlets as a strategy to provide robust prevalence
rates of substandard/falsified drugs over a potentially shorter
period.50 Quality problems highlighted by LQAS could be
further investigated with larger samples to confirm the find-
ings and to identify risk factors. Other strategies to systemat-
ically identify high-risk areas for further sampling could
include targeting areas where outlet surveys indicate high
prevalence of products that are not WHO prequalified or not
registered in-country.
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